Sublingual and oral zolpidem for insomnia disorder: a 3-month randomized trial.
CONCLUSIONS: The safety and efficacy of both zolpidem formulations are comparable. The sublingual 5 mg dose induced sleep more rapidly.
CLINICAL TRIAL REGISTRATION: NCT01896336.
PMID: 31859791 [PubMed - as supplied by publisher]
Source: Revista Brasileira de Psiquiatria - Category: Psychiatry Authors: Castro LS, Otuyama LJ, Fumo-Dos-Santos C, Tufik S, Poyares D Tags: Braz J Psychiatry Source Type: research
More News: Ambien | Clinical Trials | Headache | Insomnia | Migraine | Psychiatry | Sleep Disorders | Sleep Medicine | Women